GlassScriptPhysician profile
Kenneth R Rettig
NPI 1861431587
$1,559.88
in general payments reported to CMS, 2019-2025
19 companies · $32.94 in 2025
The $32.94 reported for 2025 was less than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $305 · 2021: $244 · 2022: $207 · 2023: $67.62 · 2024: $182 · 2025: $32.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $282.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $294.90 | 2019-2024 | Sogroya, Norditropin |
| Biogen, INC. | $246.73 | 2019 | |
| Abbvie INC. | $230.25 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $111.55 | 2020-2022 | |
| Lilly USA, LLC | $105.31 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $103.42 | 2019-2021 | |
| Pfizer INC. | $74.24 | 2019-2022 | |
| Tolmar Pharmaceuticals, INC. | $52.29 | 2020-2022 | |
| Abbott Laboratories | $47.38 | 2020-2021 | |
| Dexcom, INC. | $46.19 | 2024-2025 | Dexcom G6 Transmitter |
| Kyowa Kirin, INC. | $43.61 | 2024 | Crysvita |
| Arbor Pharmaceuticals, INC. | $41.53 | 2019-2021 | |
| Ascendis Pharma Endocrinology INC | $41.14 | 2022-2024 | |
| Biomarin Pharmaceutical INC. | $38.92 | 2022 | |
| Eton Pharmaceuticals, INC. | $21.29 | 2023 | Alkindi |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $18.45 | 2024 | |
| Amryt Pharma Holdings LTD | $16.70 | 2020 | |
| Tandem Diabetes Care, INC. | $14.35 | 2021 | |
| Insulet Corporation | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Rettig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.